Gene therapy for relapsed breast cancer

Shunji Takahashi, Yoshikazu Sugimoto

研究成果: Review article査読

抄録

Gene therapy for advanced breast cancer is anticipated to be a useful therapeutic approach. Strategies in ongoing clinical protocols can be divided into four groups: (1) suppression of oncogenes or transfer of tumor-suppressor genes: (2) enhancement of immunological response: (3) transfer of suicide genes: (4) protection of bone marrow using drug resistance genes. We have started a clinical study of multidrug resistance (MDR1) gene therapy. Patients received high dose chemotherapy and autologous peripheral blood stem cell transplantation (PBSCT) with MDR1-transduced hematopoietic cells, and then were treated with docetaxel. Three patients have been treated so far, and in vivo enrichment of MDR1-transduced cells with docetaxel treatment has been seen. There has been no apparent adverse effect from the MDR1 gene transfer.

本文言語English
ページ(範囲)563-569
ページ数7
ジャーナルNippon rinsho. Japanese journal of clinical medicine
64
3
出版ステータスPublished - 2006 3月
外部発表はい

ASJC Scopus subject areas

  • 医学一般

フィンガープリント

「Gene therapy for relapsed breast cancer」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル